Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2013
  • Online publication date: April 2013

Section 4. - Treatment of the psychiatric patient

References

1. RichmondJS, BerlinJS, FishkindAB, et al. Verbal de-escalation of the agitated patient: consensus statement of the American Association for Emergency Psychiatry Project BETA De-escalation Workgroup. West J Emerg Med 2012;13:17–25.
2. KleespiesPM. Evaluating behavioral emergencies: the clinical interview. In: KleespiesPM, (Ed.). Behavioral Emergencies: An Evidence-based Resource for Evaluating and Managing Risk of Suicide, Violence, and Victimization. Washington, DC: American Psychological Association; 2009: 33–55.
3. ZunL.Optimizing ED Neurological Emergency Patient Care 2009. Available at: http://www.ferne.onrg/Lectures/memc_2009/pdf/ferne_memc_2009_zun_agitated.pdf. (Accessed December 9, 2011).
4. HillardJ.Handbook of Emergency Psychiatry. Washington, DC: American Psychiatric Association; 1990.
5. SwiftRH, HarriganEP, CappelleriJC, KramerD, ChandlerLP. Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients. J Psychiatr Res 2002;36:87–95.
6. ChildsE.Commonwealth of Massachusetts Department of Mental Health Seclusion and Restraint Philosophy Statement. Department of Mental Health, Commonwealth of Massachusetts 2004. Available at: http://www.nasmhpd.org/general_files/publications/ntac_pubs/SR%20Project%20Huang/Huang%20I.1%20MA%20RS%20PhilosophyStatement%20-FINAL-%203.26.04.doc (Accessed August 14, 2011).
7. LazareA.Shame and humiliation in the medical encounter. Arch Intern Med 1987;147:1653–8.
8. RichmondJS, HughesDH, MilnerK, editor. Clinical Management of Violent Patients in the Emergency Room. Workshop. Institute on Psychiatric Services; 1997; Washington, DC: American Psychiatry Association.
9. MetznerJL, LionJ, ReidWH, et al. Resource document on the use of restraint and seclusion in correctional mental health care. J Am Acad Psychiatry Law 2007;35:417–25.
10. PatelY, GarmelGM.Management of intoxicated/violent patients. In: MattuA, GoyalDG, (Eds.). Emergency Medicine: Avoiding the Pitfalls and Improving the Outcomes. Malden, MA: Blackwell Publishing; 2007; 99–108.
11. VorvickL.Agitation: Overview. 2008. Available at: http://www.umm.edu/ency/article/003212trt.htm (Accessed August 26, 2011).
12. FerrisM.Protecting Hospitalized Elders from Falling: A Recent History of Fall Prevention. Topics in Advanced Practice Nursing eJournal [Internet]. Available at: http://www.medscape.com/viewarticle/585961_2 (Accessed August 26, 2011).
13. BeckJC, WhiteK, GageB. Emergency psychiatric assessment of violence. Am J Psychiatry 1991;148:1562–5.
14. SheaSC.Psychiatric Interviewing: The Art of Understanding, (2nd Edition). Philadelphia: WB Saunders; 1998.
15. NovitskyMA Jr, DubinWR. Non-pharmacological management of violence in psychiatric emergencies. Prim Psychiatry 2009;16:49–53.
16. EisendrathS, LichtmacherJE. Common psychiatric disorders: post-traumatic stress disorder. In: McPheeSJ, PapadakisM, (Eds.). Current Medical Diagnosis and Treatment, (49th Edition). New York: McGraw Hill; 2010: 938–9.
17. IsbisterGK, PageCB, StokesB, BryantJL, DownesMA. Randomized controlled trial of intramuscular droperidol versus midazolam for violence and acute behavioral disturbance: the DORM study. Ann Emerg Med 2010;56:392–401.
18. DowneyLV, ZunLS, GonzalesSJ. Frequency of alternative to restraints and seclusion and uses of agitation reduction techniques in the emergency department. Gen Hosp Psychiatry 2007;29:470–4.
19. LazareA, EisenthalS, WassermanL. The customer approach to patienthood. Arch Gen Psychiatry 1975;32:553–8.
20. BeaufordJE, McNielDE, BinderRL. Utility of the initial therapeutic alliance in evaluating psychiatric patients’ risk of violence. Am J Psychiatry 1997;154:1272–6.
21. FiskindA.Calming agitation with words not drugs. Curr Psychiatry 2002;1:32–40.
22. FishkindA.Agitation II: de-escalation of the aggressive patient and avoiding coercion. In: GlickRL, BerlinJS, FishkindA, ZellerS, (Eds.). Emergency Psychiatry: Principles and Practice. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008: 125–36.
23. SmithMJ.When I Say No, I Feel Guilty: How to Cope – Using the Skills of Systematic Assertive Therapy. New York: Dial Press; 1975.
24. PopeK, TabachnickB. Therapists’ anger, hate, fear, and sexual feelings: National survey of therapist responses, client characteristics, critical events, formal complaints, and training. Prof Psychol Res Pr 1993;24:142–52.
25. AllenMH, SheetsJ, MiccioB, et al. What do consumers say they want and need during a psychiatric emergency?J Pract Psychiatry 2003;9:29–58.
26. GuyJ, BradyJL.The stress of violent behavior for the clinician. In: KleespiesPM, (Ed.). Emergencies in Mental Health Practice Evaluation and Management. New York: Guilford Press; 1998: 398–417.
27. MalavadeKMM. A general approach to the emergency psychiatry patient. In: RibaM, RavindranathD, (Eds.). Clinical Manual of Emergency psychiatry. Washington, DC: American Psychiatric Association; 2010: 2–11.
28. LazareA.On Apology. New York: Oxford University Press; 2004.
29. LazareALevyRS. Apologizing for humiliations in medical practice. Chest 2011;139:746–51.
30. JesseS, AndersonG.Emergency services. In: LevyS, NinanP, (Eds.). Schizophrenia: Treatment of Acute Psychotic Episodes. Washington, DC: American Psychiatric Press; 1990: 27–43.

References

1. LindenmayerJP. The pathophysiology of agitation. J Clin Psychiatry 2000;61(Suppl 14):5–10.
2. ZunLS, DowneyLS. Level of agitation of psychiatric patients presenting to an emergency department. J Clin Psychiatry 2008;10:108–13.
3. WetliCV, MashD, KarchSB. Cocaine associated agitated delirium and the neuroleptic malignant syndrome. Am J Emerg Med 1996;92:110–3.
4. LaruelleM, FrankleWG, NarendranR, KegelesLS, Abi-DarghamA.Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin Ther 2005;27(Suppl 1):S16–24.
5. U.S. Food and Drug Administration. Available at: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm124830.htm (Accessed September 28, 2011).
6. U.S. Food and Drug Administration. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm173778.htm (Accessed September 28, 2011).
7. MarsdenCD, JennerP. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 1980;10:55–72.
8. JannoS, HoliM, TuiskuK, WahlbeckK. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 2004;161:160–3.
9. VinsonDR. Diphyenhydramine in the treatment of akathisia induced by prochlorperazine. J Emerg Med 2004;26:265–73.
10. GreenSM, RothrockSG, LynchEL, et al. Intramuscular ketamine for pediatric sedation in the emergency department: safety profile in 1,022 cases. Ann Emerg Med 1998;31:688–97.
11. GreenSM, RobackMG, KennedyRM, KraussB. Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update. Ann Emerg Med 2011;57:449–61.
12. MinerJM, GrayRO, BaharJ, PatelR, McGillJW. Randomized clinical trial of propofol versus ketamine for procedural sedation in the emergency department. Acad Emerg Med 2010;17:604–11.
13. SenerS, EkenC, SchuyltzCH, SerinkenM, OzsaracM. Ketamine with and without midazolam for emergency department sedation in adults: a randomized controlled trial. Ann Emerg Med 2011;57:109–14.
14. Le CongM, GyntherB, HunterE, SchullerP. Ketamine sedation for patients with acute agitation and psychiatric illness requiring aeromedical retrieval. Emerg Med J 2012;29:335–7.
15. MelamedE, OronY, Ben-AvrahamR, BlumenfeldA, LinG. The combative multitrauma patient: a protocol for prehospital management. Eur J Emerg Med 2007;14:265–8.
16. SoRelleR. ExDS protocol puts clout in EMS hands. Emergency Medicine News. September 2, 2010.
17. ZellerSL, RhoadesRW. Systematic reviews of assessment measures and pharmcologic treatment for agitation. Clin Ther 2010;32:403–25.
18. LukensTW, WoldSJ, EdlowJA, et al. Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department. Ann Emerg Med 2006;47:79–99.
19. AllenMH, CarpenterD, SheetsJL, MiccioS, RossR. What do consumers say they want and need during a psychiatric emergency?J Psychiatr Pract 2003;9:39–58.
20. LesemMD, Tran-JohnsonTK, RiesenbergRA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. B J Psychiatry 2011;198:51–8.
21. LiptzinB, JacobsonSA. Kaplan and Sadock’s. Comprehensive Textbook of Psychiatry, (9th Edition, Volume 2). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2009: 4066–73.
22. LadavacAS, DubinWR, NingA, et al. Emergency management of agitation in pregnancy. Gen Hosp Psychiatry 2007;29:39–41.
23. HeynemanE. The aggressive child. Child Adolesc Psychiatr Clin N Am 2003;12:667–77.
24. Department of Health and Human Services Centers for Medicare and Medicaid Services. Available at: www.cms.hhs.gov/CFCsAndCoPs/downloads/finalpatientrightsrule.pdf (Accessed September 30, 2011).

References

1. Bureau of Labor Statistics. Assault by Person(s), Health Care and Social Assistance, Private Industry, 2003–2007. Available at: http://www.bls.gov/opub/cwc/sh20100825ar01p1.htm (Accessed June 15, 2011).
2. KansagraSM, RaoSR, SullivanAF, et al. A survey of workplace violence across 65 U.S. emergency departments. Acad Emerg Med 2008;15:1268–74.
3. BehnamM, TillotsonRD, DavisSM, HobbsGR.Violence in the emergency department: a national survey of emergency medicine residents and attending physicians. J Emerg Med 2011;40:565–79.
4. DubinWR, NingA.Violence toward mental health professionals. In: SimonRI, TardiffK, (Eds.). Textbook of Violence Assessment and Management. Washington, DC: American Psychiatric Publishing, Inc; 2008: 461–81.
5. American College of Emergency Physicians. Emergency Department Violence: Prevention and Management. Dallas, TX: American College of Emergency Physicians; 1988.
6. OsbahrAJ, chair. Violence in the Emergency Department. Report of the Council on Science and Public Health (I-10) 2010.
7. GatesD, BossCS, McQueenL.Violence against emergency department workers. J Emerg Med 2006;31:331–7.
8. TaylorJL, RewL.A systematic review of the literature: workplace violence in the emergency department. J Clin Nurs 2010;20:1072–85.
9. KelenGD, CatlettCL.Violence in the health care setting. JAMA 2010;304:2530–1.
10. PetitJR.Management of the acutely violent patient. Psychiatr Clin N Am 2005;28:701–11.
11. GoldbergSB, LionJR.Violence in the emergency department. In: LionJR, DubinWH, FutrellD, (Eds.). Workplace Security: Effective Policies and Practices in Health Care. Chicago: Hospital Association Press; 1996: 265–76.
12. ZunLS. Evidence-based evaluation of psychiatric patients. J Emerg Med 2004;28:35–9.
13. BaronDA, DubinWR, Ning A. Other psychiatric emergencies. In: SadockBJ, SadockVA, RuizP, (Eds.). Kaplan and Sadock’s Comprehensive Textbook of Psychiatry, (9th Edition, Volume 2). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2009: 2732–45.
14. ShahSJ, FioritoM, McNamaraRM. A screening tool to medically clear psychiatric patients in the emergency department. J Emerg Med 2010 [Epub ahead of print].
15. FolsteinMF, FolsteinSE, McHughPR.“Mini-Mental State” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98.
16. NovitskyMA, JuliusRJ, DubinWR.Non-pharmacologic management of violence in psychiatric emergencies. Prim Psychiatry 2009;16:49–53.
17. RoccaP, VillariV, BogettoF.Managing the aggressive and violent patient in the psychiatric emergency. Prog Neuropsychopharmacol Biol Psychiatr 2006;30:586–91.
18. TardiffK.Clinician safety. In: TardiffK, (Ed.). Assessment and Management of Violent Patients, (2nd Edition). Washington, DC: American Psychiatric Press, Inc; 1996.
19. DrummondDJ, SparrLF, GordonGH.Hospital violence reduction among high-risk patients. JAMA 1989;261:2531–4.
20. AllenMH, CurrierGW, CarpenterD, et al. The expert consensus guideline series: treatment of behavioral emergencies. J Psychiatr Pract 2005;11(Suppl 1):1–108.
21. DubinWR.Management and treatment of violent patients. In: FlachF, (Ed.). Directions in Psychiatry, (Volume 17). New York, NY: The Hatherleigh Company; 1997.
22. EichelmanBS.Strategies for clinician safety. In: EichelmanBS, HartwigAC, (Eds.). Patient Violence and the Clinician. Washington, DC: American Psychiatric Press; 1995: 139.
23. BergAZ, BellCC, TupinJ.Clinician safety: assessing and managing violent patients. New Dir Ment Health Serv 2000;86:9–29.
24. CurrierGW, MedoriR.Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies. J Psychiatr Pract 2006;12:30–40.
25. JibsonMD.Psychopharmacology in the emergency room. J Clin Psychiatry 2007;68:796–7.
26. BattagliaJ.Pharmacological management of acute agitation. Drugs 2005;65:1207–22.
27. CurrierGW, SimpsonGM.Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001;62:153–7.
28. BattagliaJ, MossS, RushJ, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997;15:335–40.
29. CoburnVA, MycykMB.Physical and chemical restraints. Emerg Med Clin N Am 2009;27:655–67.
30. TardiffK, LionJR. Seclusion and restraint. In: SimonRI, TardiffK, Eds.). Textbook of Violence Assessment and Management. Washington, DC: American Psychiatric Publishing, Inc; 2008: 339–56.
31. LadavacAS, DubinWR, NingA, StuckemanP.Emergency management of agitation in pregnancy. Gen Hosp Psychiatry 2007;29:39–41.
32. IrvinCB, HabasRC.Weapon changes over time after initiation of a comprehensive weapon surveillance system. Am J Emerg Med 1999;17:323–4.
33. OrdogGJ, WasserbergerJ, OrdogC, AckroydG, AtluriS.Violence and general security in the emergency department. Acad Emerg Med 1995;2:151–4.
34. McNamaraR, YuDK, KellyJJ.Public perception of safety and metal detectors in an urban emergency department. Am J Emerg Med 1997;15:40–2.
35. MattoxEA, WrightSW, BracikowskiAC.Metal detectors in the pediatric emergency department: patron attitudes and national prevalence. Pediatr Emerg Care 2000;16:163–5.
36. ThompsonBM, KramerTL.Weapons screening policies and practices. In: LionJR, DubinWR, FutrellDE, (Eds.). Creating a Secure Workplace: Effective Polices and Practices in Health Care. Chicago: American Hospital Publishing, Inc; 1998: 209–34.
37. RankinsRC, HendeyGW.Effect of a security system on violent incidents and hidden weapons in the emergency department. Ann Emerg Med 1999;33:676–9.
38. BlanchardJC, CurtisKM.Violence in the emergency department. Emerg Med Clin North Am 1999;17:717–30.
39. LavoieFW, CarterGL, DanzlDF, BergRL.Emergency department violence in United States teaching hospitals. Ann Emerg Med 1988;17:1227–48.

References

1. CoburnVA, MycykMB. Physical and chemical restraints. Emerg Med Clin North Am 2009;27:655–67.
2. MahoneyBS. The extent, nature, and response to victimization of emergency nurses in Pennsylvania. J Emerg Nurs 1991;17:282–91.
3. CitromeL, VolavkaJ.Violent patients in the emergency setting. Psychiatric Clin North Am 1999;22:789–801.
4. Medicare and Medicaid Programs. Hospitals Conditions of Participation: Patients’ Rights (42 CFR Part 482). Published in the Federal Register on December 8, 2006 (Volume 71, Number 236; pages 71,378–428).
5. EvansD, WoodJ, LambertL. Patient injury and physical restraint devices: a systematic review. J Adv Nurs 2003;41:274–82.
6. MohrWK, PettiTA, MohrBD. Adverse effects associated with physical restraint. Can J Psychiatry 2003;48:330–7.
7. AnnasGJ. The last resort – the use of physical restraints in medical emergencies. N Engl J Med 1999;341:1408–12.
8. BattagliaJ, MossS, RushJ, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997;15:335–40.
9. ZunLS, DowneyL.The use of seclusion in emergency medicine. Gen Hosp Psychiatry 2005;27:365–71.
10. BetempsEJ, SomozaE, BuncherCR.Hospital characteristics, diagnosis, and staff reasons associated with use of seclusion and restraint. Hosp Community Psychiatry 1993;44:367–71.
11. WexlerDB.Seclusion and restraint: lessons from law, psychiatry, and psychology. Int J Law Psychiatry 1982;5:285–94.
12. Royal College of Psychiatrists. Not Just Bricks and Mortar. Council report CR62, Jan 1998. London: Royal College of Psychiatrists.
13. MilesSH, IrvineP.Deaths caused by physical restraints. Gerontologist 1992;32:762–6.
14. Colorado Foundation for Medical Care. Restraint Reduction. Available at: www.cms.gov/CFCsAndCoPs/downloads/restraintreduction.pdf

References

1. WilliamsJW Jr.A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000;132:743–56.
2. KatzungB, PotterW.Antidepressant agents. In: KatzungB (Eds.), Basic and Clinical Pharmacology, (Chapt. 30), New York: McGraw-Hill; 2001: 486–94.
3. LiebeltEL.Cyclic antidepressants. In: GoldfrankLR, NelsonLS, HoffmanRS, et al. (Eds.), Goldfrank’s Toxicologic Emergencies, (9th Edition, Chapt. 73), New York: McGraw-Hill; 2011.
4. CaravatiEM, BossartPJ.Demographic and electrocardiographic factors associated with severe tricyclic antidepressant toxicity. J Toxicol Clin Toxicol 1991;29:31–43.
5. BoehnertM, LovejoyFH.Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med 1985;313:474–9.
6. LiebeltEL, FrancisPD, WoolfAD. ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity. Ann Emerg Med 1995;26:195–201.
7. BeaubienAR, CarpenterDC, MathieuLF, MacConaillM, HrdinaPD.Antagonism of imipramine poisoning by anticonvulsants in the rat. Toxicol Appl Pharmacol 1976;38:1–6.
8. FoianiniA, Joseph WiegandT, BenowitzN.What is the role of lidocaine or phenytoin in tricyclic antidepressant-induced cardiotoxicity?Clin Toxicol (Phila) 2010;48:325–30.
9. BlackmanK, BrownSF, WilkesGJ.Plasma alkalinization for tricyclic antidepressant toxicity: a systematic review. Emerg Med 2001;13:204–10.
10. CarrD, BooneA, HoffmanRS, MartinK, AhluwaliaN.Successful resuscitation of a doxepin overdose using intravenous fat emulsion. Clin Toxicol 2009:47;702–65.
11. JamatyC, BaileyB, LarocqueA, et al. Lipid emulsions in the treatment of acute poisoning: a systematic review of human and animal studies. Clin Toxicol 2010;48:1–27.
12. CiprianiA.Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746–58.
13. GartlehnerG.Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med 2008;149:734–50.
14. DunkleyEJ, IsbisterGK, SibbrittD, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003;96:635–42.
15. GraudinsA, StearmanA, ChanB.Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med 1998;16:615–19.
16. BoyerEW, ShannonM.The serotonin syndrome. N Engl J Med 2005;352:1112–20.
17. CraneGE.The psychiatric effects of iproniazid. Am J Psychiatry 1956;112:494–501.
18. KrishnanKR.Revisiting monoamine oxidase inhibitors. J Clin Psychiatry 2007;68:35–41.
19. AmsterdamJD.A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transfermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003;64:208–14.
20. American Psychiatric Association. Treatment of Patients with Major Depressive Disorder {revised 2010 Nov} in American Psychiatric Association Practice Guidelines. Available at: http://psychiatryonline.org/guidelines.aspx (Accessed November 26, 2011).
21. LindenCH, RumackBH, StrehlkeC.Monoamine oxidase inhibitor overdose. Ann Emerg Med 1984;13:1137–44.
22. MartelM, MinerJR, LashkowitzS, et al. QT Prolongation and cardiac arrhythmias associated with droperidol use in critical emergency department patients. Acad Emerg Med 2003;10:510–11.
23. AlbertKK, ChuaSE.Effects on prolongation of Bazett’s corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. J Psychopharmacol 2011:25;646–66.
24. CurrierGW.Atypical antipsychotic medications in the psychiatric emergency service. J Clin Psychiatry 2000;61(Suppl 14):21–6.
25. BergJE, SlatsveK, BjorlandS, SeverC.An unexpected reaction to treatment with benzodiazepines and olanzapine in a woman with a manic condition. Clin Neuropsychol 2009;6:35–8.
26. WilsonMP, MacdonaldK, VilkeGM, FeifelD. Potential complications of combining intramusculoar olanzapine with benzodiazepines in emergency department patients. 2010 [Epub ahead of print].
27. BrookS, LuceyJV, GunnKP.Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. J Clin Psychiatry 2000;61:933–41.
28. SmithMA. Rapid dose escalation with quetiapine: a pilot study. J Clin Psychopharmacol 2005;25:331–5.
29. NgoA.Acute quetiapine overdose in adults: a 5-year retrospective case series. Ann Emerg Med 2008;52:541–7.
30. KomossaK, Rummel-KlugeC, SchmidF, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009;47:606.
31. SmithLA, CorneliusV, WarnockA, et al. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 2007;9:551–60.
32. HirschfeldRMA. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2003;1:64–110.
33. SwannAC, BowdenCL, MorrisD, et al. Depression during mania. Treatment response to lithium and divalproex. Arch Gen Psychiatry 1997;54:37–42.
34. BattagliaJ, MossS, RushJ, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997;15:335–40.
35. KaoLW, KirkMA, EversSJ, RosenfeldSH.Droperidol, QT prolongation, and sudden death: what is the evidence?Ann Emerg Med 2003;41:546–58.
36. WhitePF.Droperidol: a cost-effective antiemetic for over thirty years. Anesth Analg 95:789–90.
37. LischkeV.Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 1994;79:983–6.
38. HabibAS.Food and Drug Administration black box warning on the perioperative use of droperidol: a review of the cases. Anesth Analg 2003;96:1377–9.
39. MeehanK, ZhangF, DavidS, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001;21:389–97.
40. JonesB, TaylorCC, MeehanK.The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. J Clin Psychiatry 2001;62(Suppl 2):22–4.
41. AndrezinaR, JosiassenRC, MarcusRN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl) 2006;188:281–92.
42. Tran-JohnsonTK, Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007;68:111–19.
43. WrightP.Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158:1149–51.
44. CzellaJ.Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia related psychosis. J Clin Psychiatry 2001;62:191–8.
45. GlassmanAH.Antipsychotic drugs: prolonged QTc interval, torsades de pointes, and sudden death. Am J Psychiatry 2001;158:1774–82.

References

1. DelayJPP, LempériéreT, ElissdeB, PeigneF.Un neuroleptique majeur non-phénothiazine et nonréserpinique, l’halopéeridol, dans le traitement des psychoses. Ann Méd Psychol (Paris) 1960;118:145–52.
2. StubnerS, RustenbeckE, GrohmannR, et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 2004;37(Suppl 1):S54–64.
3. KeckPE Jr, PopeHG Jr, McElroySL.Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry 1991;148:880–2.
4. U.S. Department of Health & Human Services. HCUPnet. Rockville, Maryland 2009. Available at: http://hcupnet.ahrq.gov/ (Accessed 2011).
5. AddonizioG, SusmanVL, RothSD.Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 1987;22:1004–20.
6. LevensonJL.Neuroleptic malignant syndrome. Am J Psychiatry 1985;142:1137–45.
7. KeckPE Jr, PopeHG Jr, CohenBM, McElroySL, NierenbergAA.Risk factors for neuroleptic malignant syndrome. A case-control study. Arch Gen Psychiatry 1989;46:914–18.
8. TuralU, OnderE.Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death. Psychiatry Clin Neurosci 2010;64:79–87.
9. StrawnJR, KeckPE Jr, CaroffSN.Neuroleptic malignant syndrome. Am J Psychiatry 2007;164:870–6.
10. CaroffSN, MannSC.Neuroleptic malignant syndrome. Psychopharmacol Bull 1988;24:25–9.
11. AnanthJ, ParameswaranS, GunatilakeS, BurgoyneK, SidhomT.Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004;65:464–70.
12. BruntonLL, ParkerKL, LazoJ, BuxtonI, BlumenthalD.Goodman and Gilman’s the Pharmacological Basis of Therapeutics, (11th Edition). New York: Mcgraw-Hill; 2006.
13. ShalevA, HermeshH, MunitzH.The role of loading rate in neuroleptic malignant syndrome. Am J Psychiatry 1986;143:1059.
14. SusmanVL, AddonizioG.Reinduction of neuroleptic malignant syndrome by lithium. J Clin Psychopharmacol 1987;7:339–41.
15. GoldneyRD, SpenceND.Safety of the combination of lithium and neuroleptic drugs. Am J Psychiatry 1986;143:882–4.
16. NisijimaK, IshiguroT.Neuroleptic malignant syndrome: a study of CSF monoamine metabolism. Biol Psychiatry 1990;27:280–8.
17. GurreraRJ.Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999;156:169–80.
18. NisijimaK, IshiguroT.Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. J Psychiatr Res 1995;29:233–44.
19. SteeleD, KeltnerNL, McGuinessTM.Are neuroleptic malignant syndrome and serotonin syndrome the same syndrome?Perspect Psychiatr Care 2011;47:58–62.
20. LyonsJL, CohenAB.Selective cerebellar and basal ganglia injury in neuroleptic malignant syndrome. J Neuroimaging 2011 [Epub ahead of print].
21. ParkJW, ChoiYB, ParkSK, KimYI, LeeKS.Magnetic resonance imaging reveals selective vulnerability of the cerebellum and basal ganglia in malignant hyperthermia. Arch Neurol 2004;61:1462–3.
22. LeeS, MerriamA, KimTS, et al. Cerebellar degeneration in neuroleptic malignant syndrome: neuropathologic findings and review of the literature concerning heat-related nervous system injury. J Neurol Neurosurg Psychiatry 1989;52:387–91.
23. GurreraRJ, CaroffSN, CohenA, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the delphi method. J Clin Psychiatry 2011;72:1222–8.
24. TurnerMR, GainsboroughN.Neuroleptic malignant-like syndrome after abrupt withdrawal of baclofen. J Psychopharmacol 2001;15:61–3.
25. VelamoorVR, NormanRM, CaroffSN, et al. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis 1994;182:168–73.
26. MathewsT, AderibigbeYA.Proposed research diagnostic criteria for neuroleptic malignant syndrome. Int J Neuropsychopharmacol 1999;2:129–44.
27. PandyaM, PozueloL.A malignant neuroleptic spectrum: review of diagnostic criteria and treatment implications in three case reports. Int J Psychiatry Med 2004;34:277–85.
28. GurreraRJ, ChangSS, RomeroJA.A comparison of diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychiatry 1992;53:56–62.
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, (4th Edition). Washington, DC; American Psychiatric Association; 2004.
30. WidigerTA, SankisLM.Adult psychopathology: issues and controversies. Annu Rev Psychol 2000;51:377–404.
31. RosebushPI, MazurekMF.Serum iron and neuroleptic malignant syndrome. Lancet 1991;338:149–51.
32. MannSC, CaroffSN, BleierHR, et al. Lethal catatonia. Am J Psychiatry 1986;143:1374–81.
33. LitmanRS, RosenbergH.Malignant hyperthermia: update on susceptibility testing. JAMA 2005;293:2918–24.
34. AndersonRJ, PottsDE, GabowPA, RumackBH, SchrierRW.Unrecognized adult salicylate intoxication. Ann Intern Med 1976;85:745–8.
35. CandyJM, MorrisonC, PatonRD, LoganRW, LawsonR.Salicylate toxicity masquerading as malignant hyperthermia. Paediatr Anaesth 1998;8:421–3.
36. BouchamaA, KnochelJP.Heat stroke. N Engl J Med 2002;346:1978–88.
37. HennesseyJV.Diagnosis and management of thyrotoxicosis. Am Fam Physician 1996;54:1315–24.
38. BarronJ.Phaeochromocytoma: diagnostic challenges for biochemical screening and diagnosis. J Clin Pathol 2010;63:669–74.
39. DelacourJL, DaoudalP, ChapoutotJL, RocqB.[Therapy of neuroleptic malignant syndrome with dantrolene]. Nouv Presse Med 1981;10:3572–3.
40. ShalevA, MunitzH.The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986;73:337–47.
41. ReulbachU, DutschC, BiermannT, et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 2007;11:R4.
42. RosenbergMR, GreenM.Neuroleptic malignant syndrome. Review of response to therapy. Arch Intern Med 1989;149:1927–31.
43. DavisJM, JanicakPG, SakkasP, GilmoreC, WangZ.Electroconvulsive therapy in the treatment of the neuroleptic malignant syndrome. Convuls Ther 1991;7:111–20.
44. PeloneroAL, LevensonJL, PandurangiAK.Neuroleptic malignant syndrome: a review. Psychiatr Serv 1998;49:1163–72.
45. LevensonJL, FisherJG.Long-term outcome after neuroleptic malignant syndrome. J Clin Psychiatry 1988;49:154–6.

References

1. LindenmayerJP.The pathophysiology of agitation. J Clin Psychiatry 2000;61:5–10.
2. CaplanLR.Delirium: a neurologist’s view-the neurology of agitation and overactivity. Rev Neurol Dis 2010;7:111–18.
3. CiurliP, FormisanoR, BivonaU, et al. Neuropsychiatric disorders in persons with severe traumatic brain injury: prevalence, phenomenology, and relationship with demographic, clinical, and functional features. J Head Trauma Rehabil 2011;26:116–26.
4. DamsaC, IkelheimerD, AdamE, et al. Heisenberg in the ER: observation appears to reduce involuntary intramuscular injections in a psychiatric emergency service. Gen Hosp Psychiatry 2006;2:431–3.
5. de Araujo FilhoGM, da SilvaJM, MazettoL, MarchettiRL, YacubianEM.Psychoses of epilepsy: a study comparing the clinical features of patients with focal versus generalized epilepsies. Epilepsy Behav 2011;20:655–8.
6. WeintraubD, BurnDJ.Parkinson’s disease: the quintessential neuropsychiatric disorder. Mov Disord 2011;26:1022–31.
7. BenyaminRM, VallejoR, KramerJ, RafeyanR.Corticosteroid induced psychosis in the pain management setting. Pain Physician 2008;11:917–20.
8. LeikinJB, KrantzAJ, Zell-KanterM, et al. Clinical features and management of intoxication due to hallucinogenic drugs. Med Toxicol Adverse Drug Exp 1989;4:324–50.
9. LehmannJB, WehnerPS, LehmannCU, SavoryLM.Gender bias in the evaluation of chest pain in the emergency department. Am J Cardiol 1996;77:641–4.
10. MelishJS. Thyroid disease. In: WalkerHK, HallWD, HurstJW, (Eds.). Clinical Methods: the History, Physical, and Laboratory Examinations, (3rd Edition, Chapt. 135). Boston: Butterworths; 1990.
11. PattenSB, LavoratoDH.Medication use and major depressive syndrome in a community population. Compr Psychiatry 2001;42:124–31.
12. Millan-CalentiJC, MasedaA, RochetteS, et al. Mental and psychological conditions, medical comorbidity and functional limitation: differential associations in old adults with cognitive impairment, depressive symptoms and co-existence of both. Int J Geriatr Psychiatry 2011;26:1071–9.
13. OstlundH, KellerE, HurdYL.Estrogen receptor gene expression in relation to neuropsychiatric disorders. Ann N Y Acad Sci 2003;1007:54–63.
14. PoeschlaBD, BartleP, HansenKP.Serotonin syndrome associated with polypharmacy in the elderly. Gen Hosp Psychiatry 2011;33:301.e9–11.
15. YeeAH, WijdicksEF.A perfect storm in the emergency department. Neurocrit Care 2010;12:258–60.
16. CaroffSN, HurfordI, LybrandJ, CampbellEC.Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin 2011;29:127–48.
17. WuYF, KanYS, YangCH.Neuroleptic malignant syndrome associated with bromocriptine withdrawal in Parkinson’s disease – a case report. Gen Hosp Psychiatry 2011;33:301.e7–8.
18. GurreraRJ, CaroffSN, CohenA, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry 2011;72:1222–8.
19. BlackK, SheaC, DursunS, KutcherS.Selective serotonin re-uptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 2000;25:255–61.
20. Yasui-FurukoriN, KanekoS.Hallucination induced by paroxetine discontinuation in patients with major depressive disorders. Psychiatry Clin Neurosci 2011;65:384–5.
21. HaddadP.Antidepressant discontinuation syndromes. Clinical relevance, prevention and management. Drug Saf 2001;24:183–97.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, (4th Edition), Text Revision. Washington, DC: American Psychiatric Association; 2000.
23. BaldessariniRJ, PompiliM, TondoL.Suicide in bipolar disorder: risks and management. CNS Spectr 2006;11:465–71.
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, (4th Edition), Text Revision. Washington, DC: American Psychiatric Association; 2000:436, 474.
25. KaterndahlDA, RealiniJP.Where do panic attack sufferers seek care?J Fam Pract 1995;40:237–43.
26. SareenJ, CoxBJ, AfifiTO, et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry 2005;62:1249–57.
27. GairinI, HouseA, OwensD.Attendance at the accident and emergency department in the year before suicide: a retrospective study. Br J Psychiatry 2003;183:28–33.
28. ClaassenCA, LarkinGL.Occult suicidality in an emergency department population. Br J Psychiatry 2005;186:352–3.
29. BarskyAJ, OravEJ, BatesDW.Somatization increases medical utilization and costs independent of psychiatric and medical comborbidity. Arch Gen Psychiatry 2005;62:903–10.
30. LoweB, SpitzerRL, WilliamsJB, et al. Depression, anxiety and somatization in primary care: syndrome overlap and functional impairment. Gen Hosp Psychiatry 2008;30:191–9.
31. SimonGE, VonKorffM, PiccinelliM, et al. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999;341:1329–35.
32. LukensTW, WolfSJ, EdlowJA, et al. Clinical policy: critical issues in the diagnosis and management of the adult psychiatric patient in the emergency department. Ann Emerg Med 2006;47:79–99.
33. BrasicJ, FogelmanD.Clinician safety. Psychiatr Clin North Am 1999;22:923–40.
34. AllenMH, CurrierGW, HughesDH, DochertyJP, et al. Treatment of behavioral emergencies: a summary of the expert consensus guidelines. J Psychiatr Pract 2003;9:16–38.
35. AllenMH, CarpenterD, SheetsJL, et al. What do consumers say they want and need during a psychiatric emergency?J Psychiatr Pract 2003;9:39–58.
36. SmithSB.Restraints: retraumatization for rape victims?J Psychosoc Nurs Ment Health Serv 1995;33:23–8.
37. National Collaborating Centre for Mental Health. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. London: National Institute for Clinical Excellence (NICE); 2002.
38. AllenMH, CurrierGW, CarpenterD, et al. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract 2005;11:5–108.
39. BattagliaJ.Pharmacological management of acute agitation. Drugs 2005;65:1207–22.
40. AllenMH, CurrierGW, CarpenterD, et al. The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract 2005;11:5–108.
41. HirschfeldRM, BakerJD, WozniakP, et al. The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. J Clin Psychiatry 2003;64:841–6.
42. TamayoJM, ZarateCA, VietaE, et al. Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis. Int J Neuropsychopharmacol 2010;13:813–32.
43. VicensC, SociasI, MateuC, et al. Comparative efficacy of two primary care interventions to assist withdrawal from long term benzodiazepine use: a protocol for a clustered, randomized clinical trial. BMC Fam Pract 2011;12:23.
44. WardenD, MadhukarH, TrivediMD, et al. Early adverse events and attrition in SSRI treatment: a suicide assessment methodology study. J Clin Psychopharmacol 2010;30:259–66.
45. LeonAC, SolomonDA, LiC, et al. Antidepressants and risks of suicide and suicide attempts: a 27-year observational study. J Clin Psychiatry 2011;72:580–6.
46. SachsGS, NierenbergAA, CalabreseJR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;356:1711–22.
47. LewisJ, WinokurG.The induction of mania: a natural history study with controls. Arch Gen Psychiatry 1982;39:303–6.
48. GelenbergAJ, FreemanMP, MarkowitzJC, et al. Practice guideline for the treatment of patients with major depressive disorder, (3rd Edition). American Psychiatric Association. Am J Psychiatry 2010;167:23–4.
49. MillerCH, FleischhackerWW.Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 2000;22:73–81.
50. PoyurovskyM, PashinianA, WeizmanR, et al. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. Biol Psychiatry 2006;59:1071–7.

References

1. ZunLS, DowneyLA.Level of agitation of psychiatric patients presenting to an emergency department. Prim Care Companion J Clin Psychiatry 2008;10:108–13.
2. HirayasuY, KornM.Management of Patients with Acute Psychosis. Available at: www.medscape.org/viewarticle/420241 (Accessed October 2011).
3. ZimbroffDL.Management of acute psychosis: from emergency to stabilization. CNS Spectrum 2003;8(Suppl 2):10–15.
4. MendelowitzAJ. The utility of intramuscular ziprasidone in the management of acute psychotic agitation. Ann Clin Psychiatry 2004;16:145–54.
5. ZimbroffDL, AllenMH, BattagliaJ, et al. Best clinical practice with ziprasidone IM: update after 2 years of experience. CNS Spectr 2005;10:1–15.
6. KaragianisJL, DaweIC, ThakurA, et al. Rapid tranquilization with olanzapine in acute psychosis: a case series. J Clin Psychiatry 2001;62(Suppl 2):12–16.
7. BartkoG.New formulations of olanzapine in the treatment of acute agitation. Neuropsychopharmacol Hung 2006;8:171–8.
8. BattagliaJ.Pharmacological management of acute agitation. Drugs 2005;65:1207–22.
9. AndersonWH, KuehnleJC.Rapid treatment of acute psychosis. Am J Psychiatry 1976;133:1076–8.
10. BattagliaJ, MossS, RushH, et al. Haloperidol, lorazepam or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997;15:335–40.
11. KaoLW, KirkMA, EversSJ, RosenfeldSH.Droperidol, QT prolongation and sudden death. What is the evidence?Ann Emerg Med 2003;41:546–58.
12. GanTJ.“Black box” warning on droperdol: report of the FDA convened expert panel. Anesth Analg 2004;98:1809.
13. CurrierGW, SimpsonGM.Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001;62:153–7.
14. CurrierGW, ChouJC, FeifelD, et al. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry 2004;65:386–94.
15. VeserFH, VeserBD, McMullanJT, ZealbergJ, CurrierGW.Risperidone versus haloperidol in combination with lorazepam, in the treatment of acute agitation and psychosis: a pilot randomized, double blind placebo controlled trial. J Psychiatr Pract 2006;12:103–8.
16. BrookS, LuceyJV, GunnKP.Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprsidone I.M. Study Group. J Clin Psychiatry 2000;61:933–41.
17. LimHK, KimJJ, PaeCU, et al. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study. Neuropsychobiology 2010;62:81–6.
18. HsuWY, HuangSS, LeeBS, ChiuNYComparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward. J Clin Psychopharmacol 2010;30:230–4.
19. McAllister-WilliamsRH, FerrierIN.Rapid tranquilization: time for a reappraisal of options for parenteral therapy. Br J Psychiatry 2002;180:485–9.
20. MohrP, PecenakJ, SvestkaJ, SwinglerD, TreueerT.Treatment of acute agitation in psychotic disorders. Neuro Endocrinol Lett 2005;26:327–35.
21. LarkinGL, BeautraisAL.A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 2011:14; 1127–31.
22. DiazGranados, N, IbrahimLA, BrutscheNE, et al. Rapid resolution of suicidal ideation after a single infusion of an NMDA antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010;71:1605–11.
23. PriceR, NockMK, ChameyDS, MathewSJ.Effects of intravenous ketamine on explicit and implicit measures of suicidality. Biol Psychiatry 2009;66:522–6.